Eline-Claire Grosfeld, Brandon T. Smith, M. Santoro, Irene Lodoso-Torrecilla, J. Jansen, D. Ulrich, A. Melchiorri, David W Scott, A. Mikos, J. J. van den Beucken
{"title":"Fast dissolving glucose porogens for early calcium phosphate cement degradation and bone regeneration","authors":"Eline-Claire Grosfeld, Brandon T. Smith, M. Santoro, Irene Lodoso-Torrecilla, J. Jansen, D. Ulrich, A. Melchiorri, David W Scott, A. Mikos, J. J. van den Beucken","doi":"10.1088/1748-605X/ab5f9c","DOIUrl":null,"url":null,"abstract":"Here, we demonstrate the in vivo efficacy of glucose microparticles (GMPs) to serve as porogens within calcium phosphate cements (CPCs) to obtain a fast-degrading bone substitute material. Composites were fabricated incorporating 20 wt% GMPs at two different GMP size ranges (100–150 μm (GMP-S) and 150–300 μm (GMP-L)), while CPC containing 20 wt% poly(lactic-co-glycolic acid) microparticles (PLGA) and plain CPC served as controls. After 2 and 8 weeks implantation in a rat femoral condyle defect model, specimens were retrieved and analyzed for material degradation and bone formation. Histologically, no adverse tissue response to any of the CPC-formulations was observed. All CPC-porogen formulations showed faster degradation compared to plain CPC control, but only GMP-containing formulations showed higher amounts of new bone formation compared to plain CPC controls. After 8 weeks, only CPC-porogen formulations with GMP-S or PLGA porogens showed higher degradation compared to plain CPC controls. Overall, the inclusion of GMPs into CPCs resulted in a macroporous structure that initially accelerated the generation of new bone. These findings highlight the efficacy of a novel approach that leverages simple porogen properties to generate porous CPCs with distinct degradation and bone regeneration profiles.","PeriodicalId":9016,"journal":{"name":"Biomedical materials","volume":" ","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2019-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1088/1748-605X/ab5f9c","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedical materials","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1088/1748-605X/ab5f9c","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 7
Abstract
Here, we demonstrate the in vivo efficacy of glucose microparticles (GMPs) to serve as porogens within calcium phosphate cements (CPCs) to obtain a fast-degrading bone substitute material. Composites were fabricated incorporating 20 wt% GMPs at two different GMP size ranges (100–150 μm (GMP-S) and 150–300 μm (GMP-L)), while CPC containing 20 wt% poly(lactic-co-glycolic acid) microparticles (PLGA) and plain CPC served as controls. After 2 and 8 weeks implantation in a rat femoral condyle defect model, specimens were retrieved and analyzed for material degradation and bone formation. Histologically, no adverse tissue response to any of the CPC-formulations was observed. All CPC-porogen formulations showed faster degradation compared to plain CPC control, but only GMP-containing formulations showed higher amounts of new bone formation compared to plain CPC controls. After 8 weeks, only CPC-porogen formulations with GMP-S or PLGA porogens showed higher degradation compared to plain CPC controls. Overall, the inclusion of GMPs into CPCs resulted in a macroporous structure that initially accelerated the generation of new bone. These findings highlight the efficacy of a novel approach that leverages simple porogen properties to generate porous CPCs with distinct degradation and bone regeneration profiles.
期刊介绍:
The goal of the journal is to publish original research findings and critical reviews that contribute to our knowledge about the composition, properties, and performance of materials for all applications relevant to human healthcare.
Typical areas of interest include (but are not limited to):
-Synthesis/characterization of biomedical materials-
Nature-inspired synthesis/biomineralization of biomedical materials-
In vitro/in vivo performance of biomedical materials-
Biofabrication technologies/applications: 3D bioprinting, bioink development, bioassembly & biopatterning-
Microfluidic systems (including disease models): fabrication, testing & translational applications-
Tissue engineering/regenerative medicine-
Interaction of molecules/cells with materials-
Effects of biomaterials on stem cell behaviour-
Growth factors/genes/cells incorporated into biomedical materials-
Biophysical cues/biocompatibility pathways in biomedical materials performance-
Clinical applications of biomedical materials for cell therapies in disease (cancer etc)-
Nanomedicine, nanotoxicology and nanopathology-
Pharmacokinetic considerations in drug delivery systems-
Risks of contrast media in imaging systems-
Biosafety aspects of gene delivery agents-
Preclinical and clinical performance of implantable biomedical materials-
Translational and regulatory matters